News

News

Date Title and Summary Additional Formats
Toggle Summary Ardelyx to Present at the 2015 Leerink Global Healthcare Conference
FREMONT, Calif. , Feb. 9, 2015 /PRNewswire/ --   Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today announced that Mike Raab , President and Chief Executive Officer and David Rosenbaum Ph.D., Senior Vice
View HTML
Toggle Summary Ardelyx Reports Results from Phase 2b Clinical Trial Evaluating Tenapanor in Treating Hyperphosphatemia in Chronic Kidney Disease Patients on Hemodialysis
FREMONT, Calif. , Feb. 2, 2015 /PRNewswire/ --   Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today announced that AstraZeneca's 161-patient Phase 2b clinical trial evaluating tenapanor in
View HTML
Toggle Summary Ardelyx Appoints Jeremy S. Caldwell, Ph.D., as Executive Vice President and Chief Scientific Officer
FREMONT, Calif. , Dec. 1, 2014 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced the appointment of Jeremy S. Caldwell , Ph.D., as Executive Vice President and Chief Scientific
View HTML
Toggle Summary Ardelyx's Tenapanor Reduces Phosphorus Absorption and Protects against Vascular Calcification in Preclinical In Vivo Model of Chronic Kidney Disease
-- Data Published Online in the Journal of the American Society of Nephrology --
View HTML
Toggle Summary Ardelyx Reports Third Quarter 2014 Financial Results
Phase 2 Programs for Lead Product Candidate Tenapanor Continue to Advance in Multiple IndicationsArdelyx Updates Projected Timing of Results from Phase 2b Study in ESRD patients with HyperphosphatemiaConference Call and Webcast Today at 4:30 p.m. ET
View HTML
Toggle Summary Ardelyx to Report Third Quarter 2014 Financial Results on November 6, 2014
FREMONT, Calif. , Oct. 30, 2014 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that it will report third quarter 2014 financial results on Thursday, November 6, 2014 .
View HTML
Toggle Summary Ardelyx's Tenapanor Selected for Oral and Poster Presentations at the American Society of Nephrology's Kidney Week 2014
FREMONT, Calif. , Oct. 23, 2014 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that Ardelyx , together with its development partner, AstraZeneca (NYSE:AZN, LON:AZN), will
View HTML
Toggle Summary Ardelyx Reports Positive Results from Its Phase 2b Clinical Trial Evaluating Tenapanor in IBS-C Patients
-- Primary endpoint was met for 50 mg twice daily dosing --
View HTML
Toggle Summary Ardelyx Chief Scientific Officer, Dominique Charmot, Announces Retirement from the Company at Year-End
FREMONT, Calif. , Sept. 5, 2014 /PRNewswire/ --  Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that Dominique Charmot , Ph.D., the Company's Chief Scientific Officer, has announced his
View HTML
Toggle Summary Ardelyx Reports Second Quarter 2014 Financial Results
Successfully Completed Initial Public Offering; Raised Net Proceeds of $61.2 MillionCompany Progressing Clinical Development of Lead Candidate, Tenapanor, In Three Ongoing Phase 2 Programs
View HTML